Autolus Therapeutics (AUTL) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Pipeline and Programs - Autolus has a broad clinical-stage pipeline with 4 product candidates across 4 hematological indications and 1 solid tumor program[4] - The company is using a modular programming approach, enabling rapid innovation, with 4 next-generation versions of lead programs planned to enter clinical development in 2020[4] - AUTO1NG, a dual-targeting therapy with CD19 and CD22 CARs, is planned to enter clinical testing in H1 2020 for pediatric ALL[32] - AUTO6NG, designed to address a hostile tumor microenvironment, is planned to commence Phase 1 in H2 2020[78] AUTO1 in Adult ALL - AUTO1 is designed for long-term persistence and reduced high-grade CRS in adult ALL patients[13] - Preliminary data for AUTO1 shows an 87% CR rate in all patients and a 100% CR rate using a closed process[27] - 10 out of 15 (67%) evaluable patients treated with AUTO1 remain disease-free with a median follow-up of 11 months[22] - A potential pivotal study in adult ALL is planned, with a BLA filing targeted for Q4 2021[31] AUTO3 in DLBCL - Preliminary efficacy data for AUTO3 in DLBCL shows an overall response rate of 57% in evaluable patients, with a CR rate of 36%[42] - 4 out of 5 (80%) CRs achieved with AUTO3 are ongoing[42] - 0% severe CRS and 7% severe NT were observed with primary infusion of AUTO3[44] Financials and Manufacturing - Autolus had $229 million in cash as of September 30, 2019, providing a cash runway into H2 2021[4] - The company is expanding to new US/UK facilities and plans a commercial site with a capacity of 5,000 patients per year[4, 11]